CNS Pharmaceuticals Inc (CNSP) — Cash Flow-to-Debt Ratio
CNS Pharmaceuticals Inc (CNSP) has a Cash Flow-to-Debt Ratio of -1.01x as of March 2026, meaning its operating cash flow of $-4.65 Million could theoretically repay -1% of its total liabilities ($4.58 Million) in one year. Explore CNS Pharmaceuticals Inc cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CNS Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for CNS Pharmaceuticals Inc across 9 annual periods. Also explore CNSP total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for CNS Pharmaceuticals Inc (2017–2025)
Year-by-year debt coverage analysis for CNS Pharmaceuticals Inc. For market capitalisation and broader financial context, see market cap of CNS Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.37x | $-13.81 Million | $4.10 Million | ▲ +50.3% |
| 2024 | -6.78x | $-17.11 Million | $2.52 Million | ▼ -194.0% |
| 2023 | -2.31x | $-14.14 Million | $6.13 Million | ▼ -7.4% |
| 2022 | -2.15x | $-10.56 Million | $4.92 Million | ▲ +66.2% |
| 2021 | -6.34x | $-13.54 Million | $2.14 Million | ▼ -65.1% |
| 2020 | -3.84x | $-7.32 Million | $1.91 Million | ▲ +66.4% |
| 2019 | -11.43x | $-3.55 Million | $311.00K | ▼ -1866.0% |
| 2018 | -0.58x | $-716.38K | $1.23 Million | ▼ -14.3% |
| 2017 | -0.51x | $-112.20K | $220.73K | — |